Document Detail

Long-term outcome after venom immunotherapy.
MedLine Citation:
PMID:  20610978     Owner:  NLM     Status:  MEDLINE    
PURPOSE OF REVIEW: There have been a limited number of studies examining the outcome after discontinuing venom immunotherapy (VIT), all of which showed continued protection in the great majority of patients. Several different criteria have been proposed to select patients to stop treatment based on immunologic and clinical factors. Specific high-risk factors have been reported from these published reports. There have been very few reports of the outcome more than 5 years after stopping VIT and virtually none on patients who had discontinued treatment for more than 10 years. This review will summarize the published evidence for current guidelines and recommendations, with emphasis on long-term outcomes. RECENT FINDINGS: There has been a paucity of studies of VIT in recent years, particularly regarding long-term outcomes. These studies have raised questions about whether the long-term outcome is different with less than 3 years than with more than 3 years of treatment. Recent studies have confirmed the roughly 15% chance of systemic reaction to a sting after stopping VIT and the low risk (<3%) of a severe reaction. New and meaningful observations have been made in several reports regarding the increased risk of relapse, and even death, in patients with mastocytosis or elevated baseline serum tryptase, who had discontinued VIT. SUMMARY: This review incorporates old and new observations that provide the basis for the guidelines and practice parameters on discontinuing VIT.
David B K Golden
Related Documents :
18678758 - Factors affecting the duration of orthodontic treatment: a systematic review.
18373108 - Carbapenems versus other beta-lactams in treating severe infections in intensive care: ...
18562058 - Timing of renal replacement therapy initiation in acute renal failure: a meta-analysis.
15495028 - Prophylactic anastomotic drainage for colorectal surgery.
24585488 - Late hdv rna relapse after peginterferon alfa-based therapy of chronic hepatitis delta.
11603518 - Medial unicompartmental arthroplasty after failed high tibial osteotomy.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review    
Journal Detail:
Title:  Current opinion in allergy and clinical immunology     Volume:  10     ISSN:  1473-6322     ISO Abbreviation:  Curr Opin Allergy Clin Immunol     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-07-08     Completed Date:  2010-10-21     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100936359     Medline TA:  Curr Opin Allergy Clin Immunol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  337-41     Citation Subset:  IM    
Johns Hopkins Asthma and Allergy Center, Baltimore, Maryland 21224, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Bee Venoms / administration & dosage*,  adverse effects,  therapeutic use
Desensitization, Immunologic / methods*
Drug Administration Schedule
Hymenoptera / immunology*
Hypersensitivity, Immediate / prevention & control*,  therapy
Insect Bites and Stings / immunology
Time Factors
Treatment Outcome
Wasp Venoms / administration & dosage*,  adverse effects,  therapeutic use
Grant Support
Reg. No./Substance:
0/Bee Venoms; 0/Wasp Venoms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Editorial comment.
Next Document:  Effectiveness of Helicobacter pylori eradication in chronic urticaria: evidence-based analysis using...